Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Gains from Sales and Divestitures (2024)

Zevra Therapeutics (ZVRA) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $765945.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $765945.0, compared with a TTM value of $765945.0 through Dec 2024, changed N/A, and an annual FY2024 reading of $765945.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $765945.0 for Q4 2024 at Zevra Therapeutics.
  • Across five years, Gains from Sales and Divestitures topped out at $765945.0 in Q4 2024 and bottomed at $765945.0 in Q4 2024.